Digital Therapeutics Have Arrived But Will Insurers Get On Board?
Executive Summary
Will FDA-cleared prescription digital therapeutics be able to follow wellness, chronic disease and sleep disorder apps onto the formularies of major payers? For digital therapeutics companies investing in randomized controlled clinical trials, GMP manufacturing and FDA submissions for products, the current absence of public health insurance coverage is frustrating.
You may also be interested in...
BI Finds Right Fit For Digital Therapeutic Partnership With Click
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
Post-COVID-19 Consumer Preferences Provide Roadmap For Strategy Across Health Care Sectors
Post-COVID, a consumer’s home as point of care has led to greater acceptance for health gadgets while shifting preferences away from injectables, shows a new study, which has pointers for pharma strategy. With anxiety over the pandemic continuing, mental telehealth solutions are ripe for the picking.
Post-COVID-19 Consumer Preferences A Guide For Pharma Strategy
Post-COVID, a consumer’s home as point of care has led to greater acceptance for health gadgets while shifting preferences away from injectables, shows a new study, which has pointers for pharma strategy. With anxiety over the pandemic continuing, mental telehealth solutions are ripe for the picking, it adds.
Need a specific report? 1000+ reports available
Buy Reports